Terms: = Ovarian cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Diagnosis
182 results:
1. Trichorhinophalangeal Syndrome Type 1 Immunohistochemical Expression in Carcinomas of Gynecologic Origin.
Ruiz F; Tjendra Y; Millan N; Gomez-Fernandez C; Pinto A
Am J Surg Pathol; 2024 May; 48(5):546-550. PubMed ID: 38357982
[TBL] [Abstract] [Full Text] [Related]
2. Multifactor assessment of ovarian cancer reveals immunologically interpretable molecular subtypes with distinct prognoses.
Guo Y; Li S; Li C; Wang L; Ning W
Front Immunol; 2023; 14():1326018. PubMed ID: 38143770
[TBL] [Abstract] [Full Text] [Related]
3. An Aptamer-Based Nanoflow Cytometry Method for the Molecular Detection and Classification of ovarian cancers through Profiling of Tumor Markers on Small Extracellular Vesicles.
Li J; Li Y; Li Q; Sun L; Tan Q; Zheng L; Lu Y; Zhu J; Qu F; Tan W
Angew Chem Int Ed Engl; 2024 Jan; 63(4):e202314262. PubMed ID: 38012811
[TBL] [Abstract] [Full Text] [Related]
4. Prevalence of BRCA1 and BRCA2 Mutations Among High-risk Bahraini Patients with Breast cancer.
Bukamal Z; AlRayes A
Gulf J Oncolog; 2023 May; 1(42):22-25. PubMed ID: 37283256
[TBL] [Abstract] [Full Text] [Related]
5. Clinical efficacy of PARP inhibitors in breast cancer.
Pandya K; Scher A; Omene C; Ganesan S; Kumar S; Ohri N; Potdevin L; Haffty B; Toppmeyer DL; George MA
Breast Cancer Res Treat; 2023 Jul; 200(1):15-22. PubMed ID: 37129747
[TBL] [Abstract] [Full Text] [Related]
6. Immunohistochemical markers of prognosis in adult granulosa cell tumors of the ovary - a review.
Jung D; Almstedt K; Battista MJ; Seeger A; Jäkel J; Brenner W; Hasenburg A
J Ovarian Res; 2023 Mar; 16(1):50. PubMed ID: 36869369
[TBL] [Abstract] [Full Text] [Related]
7. Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories.
Dundr P; Bártů M; Bosse T; Bui QH; Cibula D; Drozenová J; Fabian P; Fadare O; Hausnerová J; Hojný J; Hájková N; Jakša R; Laco J; Lax SF; Matěj R; Méhes G; Michálková R; Šafanda A; Němejcová K; Singh N; Stolnicu S; Švajdler M; Zima T; Stružinská I; McCluggage WG
Mod Pathol; 2023 Jan; 36(1):100040. PubMed ID: 36788074
[TBL] [Abstract] [Full Text] [Related]
8. Impact of Anti-her2 Therapy Alone and With Weekly Paclitaxel on the ovarian Reserve of Young Women With her2-Positive Breast cancer.
Lambertini M; Ceppi M; Anderson RA; Cameron DA; Bruzzone M; Franzoi MA; Massarotti C; El-Abed S; Wang Y; Lecocq C; Nuciforo P; Rolyance R; Pusztai L; Sohn J; Latocca MM; Arecco L; Pistilli B; Ruddy KJ; Ballestrero A; Del Mastro L; Peccatori FA; Partridge AH; Saura C; Untch M; Piccart M; Di Cosimo S; de Azambuja E; Demeestere I
J Natl Compr Canc Netw; 2023 Jan; 21(1):33-41.e16. PubMed ID: 36634607
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathologic Review of Metastatic Breast cancer to the Gynecologic Tract.
Braun A; Reddy S; Cheng L; Gattuso P; Yan L
Int J Gynecol Pathol; 2023 Jul; 42(4):414-420. PubMed ID: 36563298
[TBL] [Abstract] [Full Text] [Related]
10. The role of her2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma.
Talia KL; Banet N; Buza N
Pathology; 2023 Feb; 55(1):8-18. PubMed ID: 36503635
[TBL] [Abstract] [Full Text] [Related]
11. COMMD3-Mediated Endosomal Trafficking of her2 Inhibits the Progression of ovarian Carcinoma.
Wang S; Liu Y; Li S; Chen Y; Liu Y; Yan J; Wu J; Li J; Wang L; Xiang R; Shi Y; Qin X; Yang S
Mol Cancer Res; 2023 Mar; 21(3):199-213. PubMed ID: 36445330
[TBL] [Abstract] [Full Text] [Related]
12. Clinical application of artificial neural network (ANN) modeling to predict BRCA1/2 germline deleterious variants in Chinese bilateral primary breast cancer patients.
Li Y; Chen L; Lv J; Chen X; Zeng B; Chen M; Guo W; Lin Y; Yu L; Hou J; Li J; Zhou P; Zhang W; Li S; Jin X; Cai W; Zhang K; Huang Y; Wang C; Fu F
BMC Cancer; 2022 Nov; 22(1):1125. PubMed ID: 36324133
[TBL] [Abstract] [Full Text] [Related]
13. Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin.
Du T; Pan L; Zheng C; Chen K; Yang Y; Chen J; Chao X; Li M; Lu J; Luo R; Zhang J; Wu Y; He J; Jiang D; Sun P
Breast Cancer Res; 2022 Oct; 24(1):70. PubMed ID: 36284362
[TBL] [Abstract] [Full Text] [Related]
14. TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.
Arciuolo D; Travaglino A; Raffone A; Raimondo D; Santoro A; Russo D; Varricchio S; Casadio P; Inzani F; Seracchioli R; Mollo A; Mascolo M; Zannoni GF
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232987
[TBL] [Abstract] [Full Text] [Related]
15. Gene-Expression Profiling of Mucinous ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.
Meagher NS; Gorringe KL; Wakefield M; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt KA; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DDL; ; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; ; Gourley C; Grube M; Harnett PR; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim BG; Kim JW; Kim JH; Klett K; Koziak JM; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubiński J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park SY; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; ; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F; Park SK; Staebler A; Sundfeldt K; Wu AH; Talhouk A; Pharoah PDP; Anderson L; DeFazio A; Köbel M; Friedlander ML; Ramus SJ
Clin Cancer Res; 2022 Dec; 28(24):5383-5395. PubMed ID: 36222710
[TBL] [Abstract] [Full Text] [Related]
16. [Clinical characteristics of patients with Breast and / or ovarian cancer with mutations in the BRCA1 and BRCA2 genes in Córdoba, Argentina].
Martin CA; Suárez Villasmil L; Sembaj A; Gomez Balangione F; Zunino S; Montes CDC; Borello A; Del Castillo A; Zeballos M; Rossi NT
Rev Fac Cien Med Univ Nac Cordoba; 2022 Sep; 79(3):228-234. PubMed ID: 36149077
[TBL] [Abstract] [Full Text] [Related]
17. Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype.
Zang F; Ding X; Chen J; Hu L; Sun J; Zhang J; Xu Y; Yao L; Xie Y
Breast Cancer Res Treat; 2022 Oct; 195(3):431-439. PubMed ID: 35974241
[TBL] [Abstract] [Full Text] [Related]
18. Characteristics of breast cancer patients tested for germline BRCA1/2 mutations by next-generation sequencing in Ramathibodi Hospital, Mahidol University.
Oranratnachai S; Yamkaew W; Tunteeratum A; Sukarayothin T; Iemwimangsa N; Panvichien R
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1664. PubMed ID: 35778884
[TBL] [Abstract] [Full Text] [Related]
19. "PFH/AGM-CBA/HSV-TK/LIPOSOME-Affibody": Novel Targeted Nano Ultrasound Contrast Agents for Ultrasound Imaging and Inhibited the Growth of erbb2-Overexpressing Gastric cancer Cells.
Zhou H; Liu H; Zhang Y; Xin Y; Huang C; Li M; Zhao X; Ding P; Liu Z
Drug Des Devel Ther; 2022; 16():1515-1530. PubMed ID: 35611358
[TBL] [Abstract] [Full Text] [Related]
20. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective.
Molina-Zayas M; Garrido-Navas C; García-Puche JL; Barwell J; Pedrinaci S; Atienza MM; García-Linares S; de Haro-Muñoz T; Lorente JA; Serrano MJ; Poyatos-Andújar A
Mol Genet Genomics; 2022 May; 297(3):859-871. PubMed ID: 35451682
[TBL] [Abstract] [Full Text] [Related]
[Next]
